Outcome of Board Meeting - Final Dividend (including Special Dividend), Annual General Meeting (AGM) Date & Book Closure Date
Dear Sirs,
We refer to our letter dated 7th February 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 2.30 p.m. and concluded a 6.15 p.m.
The following items were considered and approved:
Recommendation for payment of a final dividend of Rs.181 per equity share of Rs. 1O each for the year ended 31st December 2021 and a special dividend of Rs. 309 per equity share of Rs.10 each for the year ended 31st December 2021, after considering the slump sale and transfer of Company's nutraceuticals business during the year and reviewing the cash requirements for the Company's operations.
Closure of Register of Members and Share Transfer Books from for determining the eligibility of shareholders for payment of the final dividend and the special dividend.
SECURTY
TYPE
OF
BOOK CLOSURE
PURPOSE
CODE
SECURITY
SANOFI
Equity shares
16th April 2022 to 26th April
For Annual
General Meeting and payment
2022 (both days inclusive)
of Final Dividend (including Special
Dividend) for financial year 2021, if
approved by shareholders at the Annual
General Meeting of the Company to be held
on April 26, 2022 and the same will be paid
on May 4, 2022.
Please take the above information on record.
Thanking you,
Yours faithfully
For Sanofi India Limited
-,
✓'
,.
'-R.adhika Shah
Company Secretary & Compliance Officer
Membership No.: 19308
Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939
Corporate Identity Number: L24239MH1956PLC009794
Website: www.sanofiindialtd.com I www.sanofi.in
Email: igrc.sil@sanofi.com
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sanofi India Ltd. published this content on 23 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2022 14:28:06 UTC.
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
SANOFI INDIA LIMITED 
